Fabrication of injectable CuS nanocomposite hydrogels based on UCST-type polysaccharides for NIR-triggered chemo-photothermal therapy

Abstract

Nanocomposite hydrogels were readily prepared via a one-pot method with a high NIR-thermal conversion efficiency (54.6%).

Near-infrared light-responsive hydrogels via peroxide-decorated MXene-initiated polymerization

“…[12][13][14][15] In particular, light is a distinct stimulus to tune the properties of a hydrogel spatiotemporally in a remote controlled manner with great ease and convenience. 6,[16][17][18][19] During the past decade, increasing attention has been paid to near-infrared (NIR) light-absorbing materials. As opposed to UV-Vis light, NIR light has advantages of deep penetration, low energy, and little damage to structures.…”

CuS nanoparticles anchored to g-C3N4 nanosheets for photothermal ablation of bacteria

“…Among these investigated materials, the copper suldes (CuS) 18,19,[24][25][26][27][28][29][30] stand out as suitable choices for photothermal therapy because of their excellent photothermal conversion efficiency in the NIR region and high intrinsic thermal conductivity. [31][32][33] However, the low surface area and easy sedimentation hindered their widely applications in PTT as a means of eliminating trapped bacteria. Therefore, it is highly desirable to modify the CuS NPs 17,34 to obtain a novel kind of multifunctional nanomaterials with high photothermal conversion efficiency, big loading capacity, slow sedimentation, low cost and easy fabrication.…”

Injectable Hydrogels for Cancer Therapy over the Last Decade

“…Injectable nanocomposites, consisting of GG hydrogels incorporating drug-loaded nanoparticles, were proposed for the treatment of different cancer diseases. More closely, PTX-loaded liposomes were loaded on a GG hydrogel matrix and the overall system directly instilled in the urinary bladder [256]; whereas, in another work, DOX-loaded CuS nanoparticles were embedded in GG injectable hydrogels for NIR-triggered chemo-photothermal therapy of breast cancer [257].…”